nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—CA6—saliva—type 1 diabetes mellitus	0.0135	0.0544	CbGeAlD
Nilotinib—PDGFRA—penis—type 1 diabetes mellitus	0.0123	0.0496	CbGeAlD
Nilotinib—EPHB3—nerve—type 1 diabetes mellitus	0.00894	0.036	CbGeAlD
Nilotinib—EPHA4—nerve—type 1 diabetes mellitus	0.00747	0.03	CbGeAlD
Nilotinib—CDC42BPB—islet of Langerhans—type 1 diabetes mellitus	0.00581	0.0234	CbGeAlD
Nilotinib—EPHB2—retina—type 1 diabetes mellitus	0.00562	0.0226	CbGeAlD
Nilotinib—Transient ischaemic attack—Ramipril—type 1 diabetes mellitus	0.00541	0.0349	CcSEcCtD
Nilotinib—MAPK8—islet of Langerhans—type 1 diabetes mellitus	0.00525	0.0211	CbGeAlD
Nilotinib—CDC42BPB—retina—type 1 diabetes mellitus	0.00497	0.02	CbGeAlD
Nilotinib—EPHA3—retina—type 1 diabetes mellitus	0.00471	0.0189	CbGeAlD
Nilotinib—MAPK8—retina—type 1 diabetes mellitus	0.00449	0.0181	CbGeAlD
Nilotinib—Psoriasis—Ramipril—type 1 diabetes mellitus	0.00435	0.028	CcSEcCtD
Nilotinib—CDC42BPB—cardiovascular system—type 1 diabetes mellitus	0.0042	0.0169	CbGeAlD
Nilotinib—FRK—lymphoid tissue—type 1 diabetes mellitus	0.00419	0.0168	CbGeAlD
Nilotinib—CA1—nerve—type 1 diabetes mellitus	0.00414	0.0166	CbGeAlD
Nilotinib—MAP4K1—retina—type 1 diabetes mellitus	0.00408	0.0164	CbGeAlD
Nilotinib—BLK—lymphoid tissue—type 1 diabetes mellitus	0.00404	0.0162	CbGeAlD
Nilotinib—EPHB2—lymphoid tissue—type 1 diabetes mellitus	0.00399	0.0161	CbGeAlD
Nilotinib—MAPK8—cardiovascular system—type 1 diabetes mellitus	0.0038	0.0153	CbGeAlD
Nilotinib—MAPK8—kidney—type 1 diabetes mellitus	0.00372	0.0149	CbGeAlD
Nilotinib—MAPK8—pancreas—type 1 diabetes mellitus	0.00369	0.0149	CbGeAlD
Nilotinib—CA9—islet of Langerhans—type 1 diabetes mellitus	0.00342	0.0138	CbGeAlD
Nilotinib—Endocrine disorder—Ramipril—type 1 diabetes mellitus	0.0033	0.0213	CcSEcCtD
Nilotinib—TIE1—cardiovascular system—type 1 diabetes mellitus	0.00329	0.0132	CbGeAlD
Nilotinib—CA4—nerve—type 1 diabetes mellitus	0.00324	0.013	CbGeAlD
Nilotinib—MAPK8—lymphoid tissue—type 1 diabetes mellitus	0.00319	0.0128	CbGeAlD
Nilotinib—EPHB4—islet of Langerhans—type 1 diabetes mellitus	0.00316	0.0127	CbGeAlD
Nilotinib—Disturbance in attention—Ramipril—type 1 diabetes mellitus	0.00315	0.0204	CcSEcCtD
Nilotinib—EPHA2—islet of Langerhans—type 1 diabetes mellitus	0.0031	0.0125	CbGeAlD
Nilotinib—LYN—lymphoid tissue—type 1 diabetes mellitus	0.00295	0.0118	CbGeAlD
Nilotinib—Leukocytosis—Ramipril—type 1 diabetes mellitus	0.00291	0.0188	CcSEcCtD
Nilotinib—MAP4K1—lymphoid tissue—type 1 diabetes mellitus	0.0029	0.0117	CbGeAlD
Nilotinib—EPHB6—islet of Langerhans—type 1 diabetes mellitus	0.00289	0.0116	CbGeAlD
Nilotinib—Creatinine increased—Ramipril—type 1 diabetes mellitus	0.00287	0.0185	CcSEcCtD
Nilotinib—Hearing impaired—Ramipril—type 1 diabetes mellitus	0.00287	0.0185	CcSEcCtD
Nilotinib—CA7—kidney—type 1 diabetes mellitus	0.00276	0.0111	CbGeAlD
Nilotinib—CA3—cardiovascular system—type 1 diabetes mellitus	0.00258	0.0104	CbGeAlD
Nilotinib—Blood urea increased—Ramipril—type 1 diabetes mellitus	0.00258	0.0166	CcSEcCtD
Nilotinib—EPHB4—nephron tubule—type 1 diabetes mellitus	0.00255	0.0102	CbGeAlD
Nilotinib—EPHA2—nephron tubule—type 1 diabetes mellitus	0.0025	0.01	CbGeAlD
Nilotinib—Gynaecomastia—Ramipril—type 1 diabetes mellitus	0.00244	0.0158	CcSEcCtD
Nilotinib—HCK—lymphoid tissue—type 1 diabetes mellitus	0.00242	0.00973	CbGeAlD
Nilotinib—MAPK14—cardiovascular system—type 1 diabetes mellitus	0.00241	0.0097	CbGeAlD
Nilotinib—FGR—cardiovascular system—type 1 diabetes mellitus	0.0024	0.00966	CbGeAlD
Nilotinib—MAPK14—kidney—type 1 diabetes mellitus	0.00236	0.00949	CbGeAlD
Nilotinib—EPHB4—cardiovascular system—type 1 diabetes mellitus	0.00229	0.0092	CbGeAlD
Nilotinib—Photosensitivity—Ramipril—type 1 diabetes mellitus	0.00226	0.0146	CcSEcCtD
Nilotinib—EPHA2—cardiovascular system—type 1 diabetes mellitus	0.00224	0.00902	CbGeAlD
Nilotinib—Gastroenteritis—Ramipril—type 1 diabetes mellitus	0.00224	0.0144	CcSEcCtD
Nilotinib—EPHB4—kidney—type 1 diabetes mellitus	0.00224	0.009	CbGeAlD
Nilotinib—EPHB4—pancreas—type 1 diabetes mellitus	0.00222	0.00894	CbGeAlD
Nilotinib—Deafness—Ramipril—type 1 diabetes mellitus	0.00222	0.0143	CcSEcCtD
Nilotinib—TEK—cardiovascular system—type 1 diabetes mellitus	0.00219	0.0088	CbGeAlD
Nilotinib—EPHA2—pancreas—type 1 diabetes mellitus	0.00218	0.00877	CbGeAlD
Nilotinib—TEK—kidney—type 1 diabetes mellitus	0.00214	0.00861	CbGeAlD
Nilotinib—PDGFRB—islet of Langerhans—type 1 diabetes mellitus	0.00214	0.00861	CbGeAlD
Nilotinib—TEK—pancreas—type 1 diabetes mellitus	0.00213	0.00856	CbGeAlD
Nilotinib—Amnesia—Ramipril—type 1 diabetes mellitus	0.00211	0.0136	CcSEcCtD
Nilotinib—Atrial fibrillation—Ramipril—type 1 diabetes mellitus	0.00209	0.0135	CcSEcCtD
Nilotinib—Arthritis—Ramipril—type 1 diabetes mellitus	0.00204	0.0132	CcSEcCtD
Nilotinib—Hypoglycaemia—Ramipril—type 1 diabetes mellitus	0.00203	0.0131	CcSEcCtD
Nilotinib—Cardiac failure—Ramipril—type 1 diabetes mellitus	0.00203	0.0131	CcSEcCtD
Nilotinib—MAPK14—lymphoid tissue—type 1 diabetes mellitus	0.00203	0.00815	CbGeAlD
Nilotinib—FGR—lymphoid tissue—type 1 diabetes mellitus	0.00202	0.00812	CbGeAlD
Nilotinib—Hyponatraemia—Ramipril—type 1 diabetes mellitus	0.00199	0.0128	CcSEcCtD
Nilotinib—PDGFRA—cardiovascular system—type 1 diabetes mellitus	0.00198	0.00798	CbGeAlD
Nilotinib—ABL1—islet of Langerhans—type 1 diabetes mellitus	0.00191	0.00767	CbGeAlD
Nilotinib—EPHA2—lymphoid tissue—type 1 diabetes mellitus	0.00189	0.00758	CbGeAlD
Nilotinib—Blood creatinine increased—Ramipril—type 1 diabetes mellitus	0.00186	0.012	CcSEcCtD
Nilotinib—UGT1A1—kidney—type 1 diabetes mellitus	0.00185	0.00744	CbGeAlD
Nilotinib—TEK—lymphoid tissue—type 1 diabetes mellitus	0.00184	0.0074	CbGeAlD
Nilotinib—Abdominal pain upper—Ramipril—type 1 diabetes mellitus	0.00181	0.0117	CcSEcCtD
Nilotinib—Breast disorder—Ramipril—type 1 diabetes mellitus	0.00179	0.0116	CcSEcCtD
Nilotinib—CA12—kidney—type 1 diabetes mellitus	0.00179	0.0072	CbGeAlD
Nilotinib—MAP2K5—cardiovascular system—type 1 diabetes mellitus	0.00179	0.00719	CbGeAlD
Nilotinib—KIT—nephron tubule—type 1 diabetes mellitus	0.00177	0.0071	CbGeAlD
Nilotinib—Gastritis—Ramipril—type 1 diabetes mellitus	0.00176	0.0113	CcSEcCtD
Nilotinib—CSF1R—cardiovascular system—type 1 diabetes mellitus	0.00175	0.00702	CbGeAlD
Nilotinib—Influenza—Ramipril—type 1 diabetes mellitus	0.00171	0.0111	CcSEcCtD
Nilotinib—Eosinophilia—Ramipril—type 1 diabetes mellitus	0.0017	0.011	CcSEcCtD
Nilotinib—Pancreatitis—Ramipril—type 1 diabetes mellitus	0.00168	0.0108	CcSEcCtD
Nilotinib—Angina pectoris—Ramipril—type 1 diabetes mellitus	0.00167	0.0108	CcSEcCtD
Nilotinib—PDGFRA—lymphoid tissue—type 1 diabetes mellitus	0.00167	0.0067	CbGeAlD
Nilotinib—Bronchitis—Ramipril—type 1 diabetes mellitus	0.00165	0.0106	CcSEcCtD
Nilotinib—Abdominal discomfort—Ramipril—type 1 diabetes mellitus	0.00164	0.0106	CcSEcCtD
Nilotinib—ABL1—retina—type 1 diabetes mellitus	0.00163	0.00656	CbGeAlD
Nilotinib—Pancytopenia—Ramipril—type 1 diabetes mellitus	0.00163	0.0105	CcSEcCtD
Nilotinib—Neutropenia—Ramipril—type 1 diabetes mellitus	0.0016	0.0103	CcSEcCtD
Nilotinib—Upper respiratory tract infection—Ramipril—type 1 diabetes mellitus	0.00159	0.0103	CcSEcCtD
Nilotinib—KIT—cardiovascular system—type 1 diabetes mellitus	0.00159	0.00638	CbGeAlD
Nilotinib—Erectile dysfunction—Ramipril—type 1 diabetes mellitus	0.00158	0.0102	CcSEcCtD
Nilotinib—CA4—islet of Langerhans—type 1 diabetes mellitus	0.00157	0.0063	CbGeAlD
Nilotinib—Photosensitivity reaction—Ramipril—type 1 diabetes mellitus	0.00156	0.0101	CcSEcCtD
Nilotinib—Weight increased—Ramipril—type 1 diabetes mellitus	0.00156	0.0101	CcSEcCtD
Nilotinib—KIT—kidney—type 1 diabetes mellitus	0.00155	0.00624	CbGeAlD
Nilotinib—PDGFRB—cardiovascular system—type 1 diabetes mellitus	0.00155	0.00623	CbGeAlD
Nilotinib—KIT—pancreas—type 1 diabetes mellitus	0.00154	0.0062	CbGeAlD
Nilotinib—ABL1—nephron tubule—type 1 diabetes mellitus	0.00154	0.00618	CbGeAlD
Nilotinib—PDGFRB—kidney—type 1 diabetes mellitus	0.00152	0.00609	CbGeAlD
Nilotinib—Acute coronary syndrome—Ramipril—type 1 diabetes mellitus	0.00151	0.00972	CcSEcCtD
Nilotinib—PDGFRB—pancreas—type 1 diabetes mellitus	0.00151	0.00605	CbGeAlD
Nilotinib—Renal failure—Ramipril—type 1 diabetes mellitus	0.0015	0.0097	CcSEcCtD
Nilotinib—Neuropathy peripheral—Ramipril—type 1 diabetes mellitus	0.0015	0.00967	CcSEcCtD
Nilotinib—Myocardial infarction—Ramipril—type 1 diabetes mellitus	0.0015	0.00967	CcSEcCtD
Nilotinib—Jaundice—Ramipril—type 1 diabetes mellitus	0.00149	0.00961	CcSEcCtD
Nilotinib—Stomatitis—Ramipril—type 1 diabetes mellitus	0.00149	0.00961	CcSEcCtD
Nilotinib—Urinary tract infection—Ramipril—type 1 diabetes mellitus	0.00149	0.00959	CcSEcCtD
Nilotinib—Conjunctivitis—Ramipril—type 1 diabetes mellitus	0.00149	0.00959	CcSEcCtD
Nilotinib—CSF1R—lymphoid tissue—type 1 diabetes mellitus	0.00147	0.0059	CbGeAlD
Nilotinib—CA1—cardiovascular system—type 1 diabetes mellitus	0.00145	0.00583	CbGeAlD
Nilotinib—Hepatobiliary disease—Ramipril—type 1 diabetes mellitus	0.00145	0.00933	CcSEcCtD
Nilotinib—Epistaxis—Ramipril—type 1 diabetes mellitus	0.00144	0.0093	CcSEcCtD
Nilotinib—CA1—kidney—type 1 diabetes mellitus	0.00142	0.00571	CbGeAlD
Nilotinib—CA1—pancreas—type 1 diabetes mellitus	0.00141	0.00567	CbGeAlD
Nilotinib—ABL1—cardiovascular system—type 1 diabetes mellitus	0.00138	0.00555	CbGeAlD
Nilotinib—Hepatitis—Ramipril—type 1 diabetes mellitus	0.00137	0.00885	CcSEcCtD
Nilotinib—Oedema peripheral—Ramipril—type 1 diabetes mellitus	0.00135	0.00872	CcSEcCtD
Nilotinib—ABL1—kidney—type 1 diabetes mellitus	0.00135	0.00543	CbGeAlD
Nilotinib—Connective tissue disorder—Ramipril—type 1 diabetes mellitus	0.00135	0.0087	CcSEcCtD
Nilotinib—ABL1—pancreas—type 1 diabetes mellitus	0.00134	0.0054	CbGeAlD
Nilotinib—KIT—lymphoid tissue—type 1 diabetes mellitus	0.00133	0.00536	CbGeAlD
Nilotinib—Visual impairment—Ramipril—type 1 diabetes mellitus	0.00132	0.00853	CcSEcCtD
Nilotinib—PDGFRB—lymphoid tissue—type 1 diabetes mellitus	0.0013	0.00523	CbGeAlD
Nilotinib—CA2—islet of Langerhans—type 1 diabetes mellitus	0.0013	0.00523	CbGeAlD
Nilotinib—Erythema multiforme—Ramipril—type 1 diabetes mellitus	0.0013	0.00837	CcSEcCtD
Nilotinib—Tinnitus—Ramipril—type 1 diabetes mellitus	0.00128	0.00826	CcSEcCtD
Nilotinib—Flushing—Ramipril—type 1 diabetes mellitus	0.00127	0.00822	CcSEcCtD
Nilotinib—CA4—nephron tubule—type 1 diabetes mellitus	0.00126	0.00507	CbGeAlD
Nilotinib—Immune system disorder—Ramipril—type 1 diabetes mellitus	0.00124	0.008	CcSEcCtD
Nilotinib—Mediastinal disorder—Ramipril—type 1 diabetes mellitus	0.00124	0.00798	CcSEcCtD
Nilotinib—Arrhythmia—Ramipril—type 1 diabetes mellitus	0.00123	0.00791	CcSEcCtD
Nilotinib—CA1—lymphoid tissue—type 1 diabetes mellitus	0.00122	0.0049	CbGeAlD
Nilotinib—Alopecia—Ramipril—type 1 diabetes mellitus	0.00121	0.00782	CcSEcCtD
Nilotinib—Mental disorder—Ramipril—type 1 diabetes mellitus	0.0012	0.00776	CcSEcCtD
Nilotinib—Erythema—Ramipril—type 1 diabetes mellitus	0.00119	0.00771	CcSEcCtD
Nilotinib—Malnutrition—Ramipril—type 1 diabetes mellitus	0.00119	0.00771	CcSEcCtD
Nilotinib—Dysgeusia—Ramipril—type 1 diabetes mellitus	0.00117	0.00755	CcSEcCtD
Nilotinib—ABL1—lymphoid tissue—type 1 diabetes mellitus	0.00116	0.00466	CbGeAlD
Nilotinib—Muscle spasms—Ramipril—type 1 diabetes mellitus	0.00115	0.00741	CcSEcCtD
Nilotinib—CA4—cardiovascular system—type 1 diabetes mellitus	0.00113	0.00456	CbGeAlD
Nilotinib—Tremor—Ramipril—type 1 diabetes mellitus	0.00112	0.00722	CcSEcCtD
Nilotinib—CA2—retina—type 1 diabetes mellitus	0.00111	0.00447	CbGeAlD
Nilotinib—CA4—kidney—type 1 diabetes mellitus	0.00111	0.00446	CbGeAlD
Nilotinib—Ill-defined disorder—Ramipril—type 1 diabetes mellitus	0.00111	0.00715	CcSEcCtD
Nilotinib—Malaise—Ramipril—type 1 diabetes mellitus	0.00108	0.00695	CcSEcCtD
Nilotinib—Vertigo—Ramipril—type 1 diabetes mellitus	0.00107	0.00692	CcSEcCtD
Nilotinib—Syncope—Ramipril—type 1 diabetes mellitus	0.00107	0.00691	CcSEcCtD
Nilotinib—Leukopenia—Ramipril—type 1 diabetes mellitus	0.00107	0.0069	CcSEcCtD
Nilotinib—Palpitations—Ramipril—type 1 diabetes mellitus	0.00106	0.00681	CcSEcCtD
Nilotinib—Loss of consciousness—Ramipril—type 1 diabetes mellitus	0.00105	0.00677	CcSEcCtD
Nilotinib—CA2—nephron tubule—type 1 diabetes mellitus	0.00105	0.00421	CbGeAlD
Nilotinib—Cough—Ramipril—type 1 diabetes mellitus	0.00104	0.00673	CcSEcCtD
Nilotinib—Arthralgia—Ramipril—type 1 diabetes mellitus	0.00102	0.00656	CcSEcCtD
Nilotinib—Myalgia—Ramipril—type 1 diabetes mellitus	0.00102	0.00656	CcSEcCtD
Nilotinib—Chest pain—Ramipril—type 1 diabetes mellitus	0.00102	0.00656	CcSEcCtD
Nilotinib—Anxiety—Ramipril—type 1 diabetes mellitus	0.00101	0.00654	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 1 diabetes mellitus	0.00101	0.00652	CcSEcCtD
Nilotinib—Discomfort—Ramipril—type 1 diabetes mellitus	0.001	0.00648	CcSEcCtD
Nilotinib—Dry mouth—Ramipril—type 1 diabetes mellitus	0.000995	0.00642	CcSEcCtD
Nilotinib—Confusional state—Ramipril—type 1 diabetes mellitus	0.000983	0.00634	CcSEcCtD
Nilotinib—Oedema—Ramipril—type 1 diabetes mellitus	0.000975	0.00629	CcSEcCtD
Nilotinib—ABCG2—nephron tubule—type 1 diabetes mellitus	0.000969	0.0039	CbGeAlD
Nilotinib—Shock—Ramipril—type 1 diabetes mellitus	0.000959	0.00619	CcSEcCtD
Nilotinib—Nervous system disorder—Ramipril—type 1 diabetes mellitus	0.000956	0.00617	CcSEcCtD
Nilotinib—Thrombocytopenia—Ramipril—type 1 diabetes mellitus	0.000955	0.00616	CcSEcCtD
Nilotinib—Tachycardia—Ramipril—type 1 diabetes mellitus	0.000951	0.00614	CcSEcCtD
Nilotinib—Skin disorder—Ramipril—type 1 diabetes mellitus	0.000947	0.00611	CcSEcCtD
Nilotinib—Hyperhidrosis—Ramipril—type 1 diabetes mellitus	0.000942	0.00608	CcSEcCtD
Nilotinib—CA2—cardiovascular system—type 1 diabetes mellitus	0.00094	0.00378	CbGeAlD
Nilotinib—Anorexia—Ramipril—type 1 diabetes mellitus	0.000929	0.006	CcSEcCtD
Nilotinib—CA2—kidney—type 1 diabetes mellitus	0.000919	0.0037	CbGeAlD
Nilotinib—CA2—pancreas—type 1 diabetes mellitus	0.000913	0.00367	CbGeAlD
Nilotinib—Hypotension—Ramipril—type 1 diabetes mellitus	0.000911	0.00588	CcSEcCtD
Nilotinib—CYP2B6—nephron tubule—type 1 diabetes mellitus	0.000894	0.0036	CbGeAlD
Nilotinib—Musculoskeletal discomfort—Ramipril—type 1 diabetes mellitus	0.000888	0.00573	CcSEcCtD
Nilotinib—Insomnia—Ramipril—type 1 diabetes mellitus	0.000882	0.00569	CcSEcCtD
Nilotinib—CYP2C8—kidney—type 1 diabetes mellitus	0.000876	0.00352	CbGeAlD
Nilotinib—Paraesthesia—Ramipril—type 1 diabetes mellitus	0.000875	0.00565	CcSEcCtD
Nilotinib—Dyspnoea—Ramipril—type 1 diabetes mellitus	0.000869	0.00561	CcSEcCtD
Nilotinib—Dyspepsia—Ramipril—type 1 diabetes mellitus	0.000858	0.00554	CcSEcCtD
Nilotinib—Decreased appetite—Ramipril—type 1 diabetes mellitus	0.000847	0.00547	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Ramipril—type 1 diabetes mellitus	0.000842	0.00543	CcSEcCtD
Nilotinib—Fatigue—Ramipril—type 1 diabetes mellitus	0.000841	0.00542	CcSEcCtD
Nilotinib—Constipation—Ramipril—type 1 diabetes mellitus	0.000834	0.00538	CcSEcCtD
Nilotinib—Feeling abnormal—Ramipril—type 1 diabetes mellitus	0.000803	0.00518	CcSEcCtD
Nilotinib—CYP2B6—cardiovascular system—type 1 diabetes mellitus	0.000803	0.00323	CbGeAlD
Nilotinib—Gastrointestinal pain—Ramipril—type 1 diabetes mellitus	0.000797	0.00514	CcSEcCtD
Nilotinib—CYP2C9—cardiovascular system—type 1 diabetes mellitus	0.000795	0.0032	CbGeAlD
Nilotinib—CA2—lymphoid tissue—type 1 diabetes mellitus	0.00079	0.00318	CbGeAlD
Nilotinib—CYP2B6—kidney—type 1 diabetes mellitus	0.000786	0.00316	CbGeAlD
Nilotinib—Urticaria—Ramipril—type 1 diabetes mellitus	0.000774	0.005	CcSEcCtD
Nilotinib—Body temperature increased—Ramipril—type 1 diabetes mellitus	0.000771	0.00497	CcSEcCtD
Nilotinib—Abdominal pain—Ramipril—type 1 diabetes mellitus	0.000771	0.00497	CcSEcCtD
Nilotinib—Hypersensitivity—Ramipril—type 1 diabetes mellitus	0.000718	0.00463	CcSEcCtD
Nilotinib—Asthenia—Ramipril—type 1 diabetes mellitus	0.000699	0.00451	CcSEcCtD
Nilotinib—Pruritus—Ramipril—type 1 diabetes mellitus	0.00069	0.00445	CcSEcCtD
Nilotinib—CYP2B6—lymphoid tissue—type 1 diabetes mellitus	0.000675	0.00271	CbGeAlD
Nilotinib—Diarrhoea—Ramipril—type 1 diabetes mellitus	0.000667	0.0043	CcSEcCtD
Nilotinib—Dizziness—Ramipril—type 1 diabetes mellitus	0.000645	0.00416	CcSEcCtD
Nilotinib—Vomiting—Ramipril—type 1 diabetes mellitus	0.00062	0.004	CcSEcCtD
Nilotinib—Rash—Ramipril—type 1 diabetes mellitus	0.000615	0.00397	CcSEcCtD
Nilotinib—Dermatitis—Ramipril—type 1 diabetes mellitus	0.000614	0.00396	CcSEcCtD
Nilotinib—Headache—Ramipril—type 1 diabetes mellitus	0.000611	0.00394	CcSEcCtD
Nilotinib—ABCB1—islet of Langerhans—type 1 diabetes mellitus	0.000593	0.00239	CbGeAlD
Nilotinib—CYP3A4—kidney—type 1 diabetes mellitus	0.000593	0.00239	CbGeAlD
Nilotinib—CYP2D6—kidney—type 1 diabetes mellitus	0.000584	0.00235	CbGeAlD
Nilotinib—Nausea—Ramipril—type 1 diabetes mellitus	0.000579	0.00374	CcSEcCtD
Nilotinib—ABCB1—retina—type 1 diabetes mellitus	0.000507	0.00204	CbGeAlD
Nilotinib—ABCB1—nephron tubule—type 1 diabetes mellitus	0.000478	0.00192	CbGeAlD
Nilotinib—ABCB1—cardiovascular system—type 1 diabetes mellitus	0.000429	0.00173	CbGeAlD
Nilotinib—ABCB1—kidney—type 1 diabetes mellitus	0.00042	0.00169	CbGeAlD
Nilotinib—ABCB1—pancreas—type 1 diabetes mellitus	0.000417	0.00168	CbGeAlD
Nilotinib—ABCB1—lymphoid tissue—type 1 diabetes mellitus	0.000361	0.00145	CbGeAlD
Nilotinib—MAPK11—Signaling Pathways—INS—type 1 diabetes mellitus	1.25e-05	2.1e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IFNG—type 1 diabetes mellitus	1.24e-05	2.09e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GSTT1—type 1 diabetes mellitus	1.24e-05	2.08e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—INS—type 1 diabetes mellitus	1.24e-05	2.08e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—IL6—type 1 diabetes mellitus	1.24e-05	2.08e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CCR5—type 1 diabetes mellitus	1.24e-05	2.08e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—IL6—type 1 diabetes mellitus	1.24e-05	2.08e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—TYK2—type 1 diabetes mellitus	1.23e-05	2.07e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL1B—type 1 diabetes mellitus	1.23e-05	2.07e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—ERBB3—type 1 diabetes mellitus	1.23e-05	2.07e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—CD4—type 1 diabetes mellitus	1.23e-05	2.07e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—IL6—type 1 diabetes mellitus	1.23e-05	2.07e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—E2F1—type 1 diabetes mellitus	1.23e-05	2.06e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL2—type 1 diabetes mellitus	1.23e-05	2.06e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—TYK2—type 1 diabetes mellitus	1.23e-05	2.06e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL2RA—type 1 diabetes mellitus	1.22e-05	2.05e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IFNG—type 1 diabetes mellitus	1.22e-05	2.04e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IFNG—type 1 diabetes mellitus	1.21e-05	2.03e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCR5—type 1 diabetes mellitus	1.21e-05	2.03e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—STAT3—type 1 diabetes mellitus	1.21e-05	2.03e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IGF1—type 1 diabetes mellitus	1.21e-05	2.03e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—NOS3—type 1 diabetes mellitus	1.2e-05	2.02e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—NOS2—type 1 diabetes mellitus	1.2e-05	2.02e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CD4—type 1 diabetes mellitus	1.2e-05	2.02e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IGF1—type 1 diabetes mellitus	1.2e-05	2.01e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL2RA—type 1 diabetes mellitus	1.19e-05	2e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CD80—type 1 diabetes mellitus	1.19e-05	2e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—CD4—type 1 diabetes mellitus	1.18e-05	1.97e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ITPR3—type 1 diabetes mellitus	1.18e-05	1.97e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—IL6—type 1 diabetes mellitus	1.17e-05	1.97e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CD4—type 1 diabetes mellitus	1.17e-05	1.96e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—IL6—type 1 diabetes mellitus	1.17e-05	1.96e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CASP3—type 1 diabetes mellitus	1.17e-05	1.96e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—ERBB3—type 1 diabetes mellitus	1.17e-05	1.96e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL2—type 1 diabetes mellitus	1.17e-05	1.96e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—GCG—type 1 diabetes mellitus	1.17e-05	1.96e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CD80—type 1 diabetes mellitus	1.17e-05	1.96e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—EGFR—type 1 diabetes mellitus	1.17e-05	1.95e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IGF2—type 1 diabetes mellitus	1.16e-05	1.95e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IFNG—type 1 diabetes mellitus	1.16e-05	1.94e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCR5—type 1 diabetes mellitus	1.15e-05	1.93e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—type 1 diabetes mellitus	1.14e-05	1.92e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL2RA—type 1 diabetes mellitus	1.13e-05	1.9e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CD80—type 1 diabetes mellitus	1.13e-05	1.89e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—INS—type 1 diabetes mellitus	1.13e-05	1.89e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CD86—type 1 diabetes mellitus	1.12e-05	1.88e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—EGFR—type 1 diabetes mellitus	1.12e-05	1.88e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TYK2—type 1 diabetes mellitus	1.12e-05	1.87e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—IL6—type 1 diabetes mellitus	1.12e-05	1.87e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CD4—type 1 diabetes mellitus	1.12e-05	1.87e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CASP3—type 1 diabetes mellitus	1.11e-05	1.86e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL1B—type 1 diabetes mellitus	1.11e-05	1.86e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—CD4—type 1 diabetes mellitus	1.11e-05	1.86e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL2—type 1 diabetes mellitus	1.11e-05	1.86e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ITPR3—type 1 diabetes mellitus	1.11e-05	1.86e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TYK2—type 1 diabetes mellitus	1.11e-05	1.86e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—STAT3—type 1 diabetes mellitus	1.11e-05	1.86e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—HBA1—type 1 diabetes mellitus	1.11e-05	1.86e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL2—type 1 diabetes mellitus	1.11e-05	1.85e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—INS—type 1 diabetes mellitus	1.1e-05	1.85e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—EGFR—type 1 diabetes mellitus	1.1e-05	1.84e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—APOC3—type 1 diabetes mellitus	1.1e-05	1.84e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ITPR3—type 1 diabetes mellitus	1.1e-05	1.84e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—NOS3—type 1 diabetes mellitus	1.1e-05	1.84e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—IL6—type 1 diabetes mellitus	1.09e-05	1.83e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—STAT3—type 1 diabetes mellitus	1.09e-05	1.83e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IGF1—type 1 diabetes mellitus	1.09e-05	1.83e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—IL6—type 1 diabetes mellitus	1.09e-05	1.82e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL1B—type 1 diabetes mellitus	1.09e-05	1.82e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—NOS3—type 1 diabetes mellitus	1.09e-05	1.82e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ABCC8—type 1 diabetes mellitus	1.09e-05	1.82e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL2—type 1 diabetes mellitus	1.08e-05	1.82e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL1B—type 1 diabetes mellitus	1.08e-05	1.81e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—IL6—type 1 diabetes mellitus	1.08e-05	1.81e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GSTT1—type 1 diabetes mellitus	1.08e-05	1.81e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL2—type 1 diabetes mellitus	1.08e-05	1.81e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—INS—type 1 diabetes mellitus	1.07e-05	1.79e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—TYK2—type 1 diabetes mellitus	1.07e-05	1.79e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—E2F1—type 1 diabetes mellitus	1.06e-05	1.78e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—IL6—type 1 diabetes mellitus	1.06e-05	1.78e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—IL6—type 1 diabetes mellitus	1.06e-05	1.78e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—IL6—type 1 diabetes mellitus	1.06e-05	1.77e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—INS—type 1 diabetes mellitus	1.05e-05	1.77e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—HBA1—type 1 diabetes mellitus	1.04e-05	1.75e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—APOC3—type 1 diabetes mellitus	1.04e-05	1.74e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—IL6—type 1 diabetes mellitus	1.04e-05	1.74e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—HBA1—type 1 diabetes mellitus	1.03e-05	1.73e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—STAT3—type 1 diabetes mellitus	1.03e-05	1.73e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IGF1—type 1 diabetes mellitus	1.03e-05	1.73e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL1B—type 1 diabetes mellitus	1.03e-05	1.73e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—APOC3—type 1 diabetes mellitus	1.03e-05	1.72e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL2—type 1 diabetes mellitus	1.03e-05	1.72e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CD80—type 1 diabetes mellitus	1.02e-05	1.71e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GSTT1—type 1 diabetes mellitus	1.02e-05	1.71e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ERBB3—type 1 diabetes mellitus	1.01e-05	1.69e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GSTT1—type 1 diabetes mellitus	1.01e-05	1.69e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TYK2—type 1 diabetes mellitus	1.01e-05	1.69e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—STAT3—type 1 diabetes mellitus	1.01e-05	1.69e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—EGFR—type 1 diabetes mellitus	1.01e-05	1.69e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IFNG—type 1 diabetes mellitus	9.99e-06	1.68e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CD80—type 1 diabetes mellitus	9.97e-06	1.67e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCR5—type 1 diabetes mellitus	9.93e-06	1.67e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—EGFR—type 1 diabetes mellitus	9.92e-06	1.66e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—NOS3—type 1 diabetes mellitus	9.89e-06	1.66e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GCG—type 1 diabetes mellitus	9.88e-06	1.66e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CAT—type 1 diabetes mellitus	9.88e-06	1.66e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—TYK2—type 1 diabetes mellitus	9.85e-06	1.65e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—STAT3—type 1 diabetes mellitus	9.82e-06	1.65e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL2RA—type 1 diabetes mellitus	9.79e-06	1.64e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—NOS3—type 1 diabetes mellitus	9.67e-06	1.62e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—ALB—type 1 diabetes mellitus	9.66e-06	1.62e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD4—type 1 diabetes mellitus	9.65e-06	1.62e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—INS—type 1 diabetes mellitus	9.62e-06	1.61e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TYK2—type 1 diabetes mellitus	9.54e-06	1.6e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—STAT3—type 1 diabetes mellitus	9.54e-06	1.6e-05	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—ALB—type 1 diabetes mellitus	9.47e-06	1.59e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CD80—type 1 diabetes mellitus	9.45e-06	1.58e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—INS—type 1 diabetes mellitus	9.42e-06	1.58e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—EGFR—type 1 diabetes mellitus	9.39e-06	1.57e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NOS3—type 1 diabetes mellitus	9.36e-06	1.57e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—STAT3—type 1 diabetes mellitus	9.34e-06	1.57e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CASP3—type 1 diabetes mellitus	9.31e-06	1.56e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—STAT3—type 1 diabetes mellitus	9.31e-06	1.56e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IGF1—type 1 diabetes mellitus	9.3e-06	1.56e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL2—type 1 diabetes mellitus	9.3e-06	1.56e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—type 1 diabetes mellitus	9.3e-06	1.56e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—NOS3—type 1 diabetes mellitus	9.24e-06	1.55e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CASP3—type 1 diabetes mellitus	9.23e-06	1.55e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL2—type 1 diabetes mellitus	9.21e-06	1.54e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—EGFR—type 1 diabetes mellitus	9.16e-06	1.54e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—STAT3—type 1 diabetes mellitus	9.11e-06	1.53e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IGF1—type 1 diabetes mellitus	9.11e-06	1.53e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—STAT3—type 1 diabetes mellitus	9.07e-06	1.52e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—IL6—type 1 diabetes mellitus	8.96e-06	1.5e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—INS—type 1 diabetes mellitus	8.94e-06	1.5e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—INS—type 1 diabetes mellitus	8.93e-06	1.5e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—EGFR—type 1 diabetes mellitus	8.93e-06	1.5e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL1B—type 1 diabetes mellitus	8.91e-06	1.49e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CD4—type 1 diabetes mellitus	8.91e-06	1.49e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL2—type 1 diabetes mellitus	8.88e-06	1.49e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—EGFR—type 1 diabetes mellitus	8.67e-06	1.45e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—STAT3—type 1 diabetes mellitus	8.64e-06	1.45e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IGF1—type 1 diabetes mellitus	8.64e-06	1.45e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GCG—type 1 diabetes mellitus	8.61e-06	1.44e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TYK2—type 1 diabetes mellitus	8.59e-06	1.44e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—STAT3—type 1 diabetes mellitus	8.59e-06	1.44e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—KCNJ11—type 1 diabetes mellitus	8.58e-06	1.44e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—EGFR—type 1 diabetes mellitus	8.49e-06	1.42e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—EGFR—type 1 diabetes mellitus	8.46e-06	1.42e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IL6—type 1 diabetes mellitus	8.46e-06	1.42e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NOS3—type 1 diabetes mellitus	8.44e-06	1.41e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TYK2—type 1 diabetes mellitus	8.41e-06	1.41e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CASP3—type 1 diabetes mellitus	8.4e-06	1.41e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL2—type 1 diabetes mellitus	8.39e-06	1.41e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CAT—type 1 diabetes mellitus	8.36e-06	1.4e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—EGFR—type 1 diabetes mellitus	8.28e-06	1.39e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NOS3—type 1 diabetes mellitus	8.26e-06	1.38e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—EGFR—type 1 diabetes mellitus	8.24e-06	1.38e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—ALB—type 1 diabetes mellitus	8.2e-06	1.37e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CD80—type 1 diabetes mellitus	8.17e-06	1.37e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GCG—type 1 diabetes mellitus	8.11e-06	1.36e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GCG—type 1 diabetes mellitus	8.04e-06	1.35e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TYK2—type 1 diabetes mellitus	7.98e-06	1.34e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CASP3—type 1 diabetes mellitus	7.95e-06	1.33e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL2—type 1 diabetes mellitus	7.94e-06	1.33e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—EGFR—type 1 diabetes mellitus	7.85e-06	1.32e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—NOS3—type 1 diabetes mellitus	7.84e-06	1.32e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NOS3—type 1 diabetes mellitus	7.83e-06	1.31e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—STAT3—type 1 diabetes mellitus	7.83e-06	1.31e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—EGFR—type 1 diabetes mellitus	7.81e-06	1.31e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—STAT3—type 1 diabetes mellitus	7.75e-06	1.3e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—IL6—type 1 diabetes mellitus	7.73e-06	1.3e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—INS—type 1 diabetes mellitus	7.72e-06	1.29e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL6—type 1 diabetes mellitus	7.62e-06	1.28e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—STAT3—type 1 diabetes mellitus	7.47e-06	1.25e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IGF1—type 1 diabetes mellitus	7.47e-06	1.25e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CAT—type 1 diabetes mellitus	7.29e-06	1.22e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ITPR3—type 1 diabetes mellitus	7.24e-06	1.21e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL6—type 1 diabetes mellitus	7.22e-06	1.21e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CASP3—type 1 diabetes mellitus	7.16e-06	1.2e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL2—type 1 diabetes mellitus	7.15e-06	1.2e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—EGFR—type 1 diabetes mellitus	7.11e-06	1.19e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—STAT3—type 1 diabetes mellitus	7.06e-06	1.18e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—EGFR—type 1 diabetes mellitus	7.05e-06	1.18e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—IL6—type 1 diabetes mellitus	7.04e-06	1.18e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CASP3—type 1 diabetes mellitus	7.01e-06	1.18e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL2—type 1 diabetes mellitus	7e-06	1.17e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TYK2—type 1 diabetes mellitus	6.9e-06	1.16e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—STAT3—type 1 diabetes mellitus	6.9e-06	1.16e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CAT—type 1 diabetes mellitus	6.86e-06	1.15e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL6—type 1 diabetes mellitus	6.86e-06	1.15e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—HBA1—type 1 diabetes mellitus	6.82e-06	1.14e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CAT—type 1 diabetes mellitus	6.81e-06	1.14e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—EGFR—type 1 diabetes mellitus	6.79e-06	1.14e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—APOC3—type 1 diabetes mellitus	6.78e-06	1.14e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NOS3—type 1 diabetes mellitus	6.77e-06	1.14e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—STAT3—type 1 diabetes mellitus	6.68e-06	1.12e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—IL6—type 1 diabetes mellitus	6.66e-06	1.12e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTT1—type 1 diabetes mellitus	6.65e-06	1.12e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CASP3—type 1 diabetes mellitus	6.65e-06	1.11e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL2—type 1 diabetes mellitus	6.64e-06	1.11e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—INS—type 1 diabetes mellitus	6.56e-06	1.1e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL6—type 1 diabetes mellitus	6.52e-06	1.09e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL6—type 1 diabetes mellitus	6.5e-06	1.09e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—EGFR—type 1 diabetes mellitus	6.41e-06	1.08e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL6—type 1 diabetes mellitus	6.37e-06	1.07e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL6—type 1 diabetes mellitus	6.34e-06	1.06e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—EGFR—type 1 diabetes mellitus	6.27e-06	1.05e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—EGFR—type 1 diabetes mellitus	6.07e-06	1.02e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL6—type 1 diabetes mellitus	6.03e-06	1.01e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—STAT3—type 1 diabetes mellitus	6.02e-06	1.01e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ALB—type 1 diabetes mellitus	6.01e-06	1.01e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—IL6—type 1 diabetes mellitus	6e-06	1.01e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—STAT3—type 1 diabetes mellitus	5.89e-06	9.88e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—NOS3—type 1 diabetes mellitus	5.75e-06	9.64e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CASP3—type 1 diabetes mellitus	5.75e-06	9.64e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL2—type 1 diabetes mellitus	5.74e-06	9.62e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—STAT3—type 1 diabetes mellitus	5.59e-06	9.37e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—INS—type 1 diabetes mellitus	5.55e-06	9.31e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EGFR—type 1 diabetes mellitus	5.47e-06	9.17e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL6—type 1 diabetes mellitus	5.47e-06	9.17e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL6—type 1 diabetes mellitus	5.42e-06	9.08e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EGFR—type 1 diabetes mellitus	5.36e-06	8.98e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GCG—type 1 diabetes mellitus	5.3e-06	8.89e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL6—type 1 diabetes mellitus	5.22e-06	8.75e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ALB—type 1 diabetes mellitus	5.09e-06	8.53e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EGFR—type 1 diabetes mellitus	5.08e-06	8.51e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL6—type 1 diabetes mellitus	4.93e-06	8.27e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—NOS3—type 1 diabetes mellitus	4.87e-06	8.16e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—INS—type 1 diabetes mellitus	4.84e-06	8.11e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—STAT3—type 1 diabetes mellitus	4.83e-06	8.1e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—IL6—type 1 diabetes mellitus	4.82e-06	8.08e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL6—type 1 diabetes mellitus	4.67e-06	7.82e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—INS—type 1 diabetes mellitus	4.56e-06	7.64e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—INS—type 1 diabetes mellitus	4.52e-06	7.57e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CAT—type 1 diabetes mellitus	4.49e-06	7.53e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ALB—type 1 diabetes mellitus	4.43e-06	7.43e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EGFR—type 1 diabetes mellitus	4.39e-06	7.36e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—NOS3—type 1 diabetes mellitus	4.24e-06	7.11e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL6—type 1 diabetes mellitus	4.2e-06	7.05e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ALB—type 1 diabetes mellitus	4.18e-06	7.01e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ALB—type 1 diabetes mellitus	4.14e-06	6.94e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL6—type 1 diabetes mellitus	4.12e-06	6.9e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—NOS3—type 1 diabetes mellitus	4e-06	6.7e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—NOS3—type 1 diabetes mellitus	3.96e-06	6.64e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL6—type 1 diabetes mellitus	3.9e-06	6.54e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL6—type 1 diabetes mellitus	3.37e-06	5.66e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—INS—type 1 diabetes mellitus	2.98e-06	5e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ALB—type 1 diabetes mellitus	2.73e-06	4.58e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NOS3—type 1 diabetes mellitus	2.61e-06	4.38e-06	CbGpPWpGaD
